Brief: Frequency Therapeutics Announces Topline Results For Its Phase 2B Study Of FX-322

Korro Bio

13/02/2023 13:25

Feb 13 (Reuters) - Frequency Therapeutics Inc  FREQ.O :
    * FREQUENCY THERAPEUTICS ANNOUNCES TOPLINE RESULTS FOR ITS
PHASE
2B STUDY OF FX-322 FOR THE TREATMENT OF SENSORINEURAL HEARING
LOSS
    * FREQUENCY THERAPEUTICS INC - FX-322-208 STUDY FAILS TO
MEET
PRIMARY ENDPOINT
    * FREQUENCY THERAPEUTICS INC - WILL NOW FOCUS ON ADVANCING
ITS
PROGRAM IN REMYELINATION FOR MULTIPLE SCLEROSIS
    * FREQUENCY THERAPEUTICS INC - WILL ALSO EXPLORE STRATEGIC
FINANCING ALTERNATIVES
    * FREQUENCY THERAPEUTICS - FX-322-208 STUDY FAILS TO MEET
PRIMARY
ENDPOINT, SHOWING NO SIGNIFICANT SEPARATION IN SPEECH PERCEPTION
BETWEEN FX-322 & PLACEBO
    * FREQUENCY THERAPEUTICS INC - COMPANY WILL NOW DISCONTINUE
FX-322
DEVELOPMENT PROGRAM
    * FREQUENCY THERAPEUTICS INC - PLANS TO BEGIN ITS CLINICAL
PROGRAM
FOR REMYELINATION IN 1H 2024
    * FREQUENCY THERAPEUTICS INC - THERE WERE ALSO NO MEASURABLE
IMPROVEMENTS OBSERVED IN ANY OF STUDY'S SECONDARY ENDPOINTS
    * FREQUENCY THERAPEUTICS INC - DOWNSIZING PERSONNEL BY
APPROXIMATELY 55 PERCENT
    * FREQUENCY THERAPEUTICS INC - RESTRUCTURING WILL GENERATE
SUFFICIENT COST SAVINGS TO EXTEND ITS RUNWAY INTO 2025
    * FREQUENCY THERAPEUTICS INC - RESTRUCTURING WILL GENERATE
SUFFICIENT COST SAVINGS TO EXTEND ITS RUNWAY INTO 2025
    * FREQUENCY THERAPEUTICS INC - CEO DAVID LUCCHINO IS ON
TEMPORARY
MEDICAL LEAVE AFTER HAVING BEEN HOSPITALIZED WITH BACTERIAL
MENINGITIS
    * FREQUENCY THERAPEUTICS INC -  BOARD HAS APPOINTED CHRIS
LOOSE,
CSO, AS INTERIM CEO UNTIL MR. LUCCHINO RETURNS
    * FREQUENCY THERAPEUTICS INC -  RESTRUCTURING WILL ENABLE CO
TO
COMPLETE A FIRST CLINICAL TRIAL OF ITS MS PROGRAM IN 2H 2024

Source text for Eikon:  ID:nBw8K8CgTa 
Further company coverage:  FREQ.O 
 ((Reuters.Briefs@thomsonreuters.com;))